Proactive Investors - Run By Investors For Investors

OptiBiotix surges as SlimBiome granted CE mark and medical device status

The CE mark allows the product to be marketed within the EEA, as well as providing eligibility for shortened medical product registration in markets such as China and the UAE
Weight loss
SlimBiome is marketed as a weight management system

Shares in OptiBiotix Health plc (LON:OPTI) surged in early trading Tuesday after its SlimBiome weight loss product received a CE mark as well as medical device status.

The CE mark allows the product to be freely marketed within the European Economic Area (EEA), as well as providing eligibility for shortened medical product registration procedures in other markets such as China and the United Arab Emirates.

READ: OptiBiotix Health inks distribution deal covering Greece and Cyprus

CE-marked products may also make medicinal or medical claims supported by clinical studies, a factor that would extend the application of SlimBiome from food products to medical products.

The company added that the product will be manufactured in Europe and sold as SlimBiome Medical to pharmacies and major retailers.

Stephen O'Hara, chief executive of OptiBiotix, said the new mark and status for SlimBiome would open up access to consumer healthcare and pharmaceutical markets, adding that in combination with “a number of clinical studies showing SlimBiome's effectiveness, a large IP portfolio [and] two industry awards”, there were now “clear differentiators” from other weight loss products which he hoped would “contribute substantive revenues to OptiBiotix's growth”.

The development follows other European news last week when the firm clinched a three-year distribution contract in Greece and Cyprus for its LPLDL cholesterol and blood pressure product.

Shares were up 17.8% at 86p.

--Adds share price--

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
woman touching her skin
May 21 2019
Here we take a closer look at Integumen PLC (LON:SKIN), which has developed and digitised an artificial skin

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use